HCPCS Codes Similar to J1326

HCPCS Codes Similar to “J1326” Code.
Injection, zolbetuximab-clzb, 2 mg

C9303 Injection, zolbetuximab-clzb, 1 mg Code added date: 20250401 Code effective date: 20250701 TXT \| PDF \| XML \| JSON	C9024 Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine Code added date: 20180101 Code effective date: 20190101 TXT \| PDF \| XML \| JSON
C9066 Injection, sacituzumab govitecan-hziy, 2.5 mg Code added date: 20201001 Code effective date: 20210101 TXT \| PDF \| XML \| JSON	C9070 Injection, tafasitamab-cxix, 2 mg Code added date: 20210101 Code effective date: 20210401 TXT \| PDF \| XML \| JSON
C9164 Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg) Code added date: 20240101 Code effective date: 20240401 TXT \| PDF \| XML \| JSON	C9291 Injection, aflibercept, 2 mg vial Code added date: 20120401 Code effective date: 20120701 TXT \| PDF \| XML \| JSON
C9302 Injection, zanidatamab-hrii, 2 mg Code added date: 20250401 Code effective date: 20250701 TXT \| PDF \| XML \| JSON	G0532 Take-home supply of nasal nalmefene hydrochloride; one carton of two, 2.7 mg per 0.1 ml nasal sprays (provision of the services by a medicare-enrolled opioid treatment program);( list separately in addition to each primary code) Code added date: 20250101 Code effective date: 20250101 TXT \| PDF \| XML \| JSON
G2082 Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation Code added date: 20200101 Code effective date: 20200101 TXT \| PDF \| XML \| JSON	G2083 Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation Code added date: 20200101 Code effective date: 20200101 TXT \| PDF \| XML \| JSON
G9676 Patients aged 40 to 75 years at the beginning of the measurement period with type 1 or type 2 diabetes and with an ldl-c result of 70-189 mg/dl recorded as the highest fasting or direct laboratory test result in the measurement year or during the two years prior to the beginning of the measurement period Code added date: 20160101 Code effective date: 20160101 TXT \| PDF \| XML \| JSON	J0172 Injection, aducanumab-avwa, 2 mg Code added date: 20220101 Code effective date: 20220407 TXT \| PDF \| XML \| JSON
J0175 Injection, donanemab-azbt, 2 mg Code added date: 20240702 Code effective date: 20240702 TXT \| PDF \| XML \| JSON	J0458 Injection, aztreonam/avibactam, 7.5 mg/2.5 mg (10 mg) Code added date: 20251001 Code effective date: 20251001 TXT \| PDF \| XML \| JSON